¸ÞÅäÆ®·º¼¼ÀÌÆ® °æ±¸º¹¿ë ÈÄ ¹ß»ýÇÑ °¡¿ª¼Ò³ú¹éÁú³úº´Áõ
Reversible Cerebellar Leukoencephalopathy Associated With Oral Methotrexate
´ëÇѽŰæ°úÇÐȸÁö 2014³â 32±Ç 3È£ p.168 ~ p.170
ÀÌÁÖ¿¬(Lee Ju-Youn) - Ãæ³²´ëÇб³ ÀÇ°ú´ëÇÐ Ãæ³²´ëÇб³º´¿ø ½Å°æ°ú
¿ÀÀÀ¼®(Oh Eung-Seok) - Ãæ³²´ëÇб³ ÀÇ°ú´ëÇÐ Ãæ³²´ëÇб³º´¿ø ½Å°æ°ú
Á¤¼ºÇØ(Jeong Seong-Hae) - Ãæ³²´ëÇб³ ÀÇ°ú´ëÇÐ Ãæ³²´ëÇб³º´¿ø ½Å°æ°ú
¼ÕÀºÈñ(Sohn Eun-Hee) - Ãæ³²´ëÇб³ ÀÇ°ú´ëÇÐ Ãæ³²´ëÇб³º´¿ø ½Å°æ°ú
Àֿ̾µ(Lee Ae-Young) - Ãæ³²´ëÇб³ ÀÇ°ú´ëÇÐ Ãæ³²´ëÇб³º´¿ø ½Å°æ°ú
Abstract
Methotrexate (MTX)-induced leukoencephalopathy is the most often reported leukoencephalopathy following intrathecal or intravenous administration. A 72-year-old woman developed leukoencephalopathy localized to the cerebellum after treatment with oral MTX at a dose of 15 mg/week for 3 years. She complained of subtle imbalance during walking and reported having fallen. Her symptoms improved after discontinuation of MTX, and the leukoencephalopathy resolved. This is therefore a case report of selective cerebellar reversible leukoencephalopathy associated with oral MTX.
Å°¿öµå
Leukoencephalopathy, Methotrexate, Cerebellum
KMID :
0359720140320030168
¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸
µîÀçÀú³Î Á¤º¸
À¯È¿¼º°á°ú(Recomendation)